Kn 92

Manufactured by Santa Cruz Biotechnology

KN-92 is a laboratory reagent primarily used in cell and molecular biology research. It functions as a protein kinase inhibitor. The core purpose of KN-92 is to serve as a tool for studying cellular signaling pathways and processes involving protein kinases. Detailed information about the intended use or application of KN-92 is not available in this concise, unbiased, and factual description.

Automatically generated - may contain errors

Lab products found in correlation

Peristaltic pump, by Cole-Parmer (1 mentions) Igf 1, by R&D Systems (1 mentions) Basic fibroblast growth factor (bfgf), by R&D Systems (1 mentions) Hepatocyte growth factor (hgf), by R&D Systems (1 mentions)

3 protocols using kn 92

Ion Channel Blockers and Signaling Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bath‐applied drugs were administered to the slice via a peristaltic pump purchased from Cole‐Palmer (colepalmer.com), and a three‐way valve system such that solutions reached the slice 1.5 min after the start of application. Tetrodotoxin (TTX, Na⁺ channel blocker), tetraethylammonium (TEA‐Cl, K⁺ channel blockers), Cesium (Cs⁺, K⁺ channel blocker), and the synaptic blockers (SBs) listed below, were purchased from Sigma Aldrich (sigmaaldrich.com). ω‐Agatoxin‐IVA (Aga; 100 nmol/L), a specific P/Q‐type channel blocker. ω‐Conotoxin‐GVIA (CgTx; 2.5 μmol/L), a specific N‐type channel blocker. These Ca²⁺ channel blockers were purchased from Alomone labs (alomone.com). KN‐93, a selective inhibitor of Ca²⁺/calmodulin‐dependent kinase type II (CaMKII), was purchased from Cayman (caymanchem.com). KN‐92 (10 μmol/L), an inactive derivative of KN‐93, was purchased from Santa Cruz Biotechnology (scbt.com). H89, a protein kinase inhibitor, was purchased from Tocris (tocris.com).

Luster B.R., Urbano F.J, & Garcia‐Rill E. (2016). Intracellular mechanisms modulating gamma band activity in the pedunculopontine nucleus (PPN). Physiological Reports, 4(12), e12787.

+ Open protocol

+ Expand

Growth Factor Preparation and Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant VEGF₁₆₅, bFGF, HGF, IGF-1, and PDGF were obtained from R&D Systems. The CAMKII inhibitor KN93 and its inactive analogue KN92 were purchased from Santa Cruz Biotechnology Inc. CK59 was obtained from Calbiochem. Stock solutions of growth factors were prepared in PBS, while pharmacological agents were dissolved in DMSO. The DMSO concentration in the assays never exceeded 0.1% (vol/vol), a concentration that was found not to influence the results of any of the assays.

Ashraf S., Bell S., O’Leary C., Canning P., Micu I., Fernandez J.A., O’Hare M., Barabas P., McCauley H., Brazil D.P., Stitt A.W., McGeown J.G, & Curtis T.M. (2019). CAMKII as a therapeutic target for growth factor–induced retinal and choroidal neovascularization. JCI Insight, 4(6), e122442.

+ Open protocol

+ Expand

Modulators of Synaptic Plasticity Mechanisms

Check if the same lab product or an alternative is used in the 5 most similar protocols

All chemicals were purchased from Tocris Bioscience (R&D Systems, Minneapolis MN) except where indicated. D3PVP [deamino-Cys¹, D-3-(pyridyl)-Ala², Arg⁸-Avp] and [dLeu⁴,Lys⁸]-Avp were used as selective Avp1b receptor agonists. Oxt and [Thr⁴,Gly⁷]-Oxt (American Peptide Co., Sunnyvale, CA) were used as agonists of the Oxtr. The following drugs were used to interfere with known regulators of synaptic plasticity: BAPTA [1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid], a selective calcium chelator; KN-62 [4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1 piperazinyl)propyl] phenyl isoquinolinesulfonic acid ester], and KN-93 [N-[2-[[[3-(4-chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulphonamide], cell-permeable inhibitors of calcium/calmodulin-dependent protein kinase II alpha (CaMKII); PKI [protein kinase A (PKA) inhibitor fragment (6-22) amide], an inhibitor of the catalytic subunit of cAMP-dependent protein kinases; D-(-)-2-Amino-5-phosphonopentanoic acid (AP5), a competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist; and bicuculline, a competitive antagonist of GABA_A receptors. KN-92 [2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine, monohydrochloride] is an inactive analog of KN-93 (Santa Cruz Biotechnology, Dallas, TX).

Pagani J.H., Zhao M., Cui Z., Williams Avram S.K., Caruana D.A., Dudek S.M, & Young WS 3.r.d. (2014). Role of the Vasopressin 1b Receptor in Rodent Aggressive Behavior and Synaptic Plasticity in Hippocampal Area CA2. Molecular psychiatry, 20(4), 490-499.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!